Workflow
江中药业(600750) - 2022 Q1 - 季度财报
JZYYJZYY(SH:600750)2022-04-22 16:00

Financial Performance - The company's operating revenue for Q1 2022 was ¥930,726,704.79, representing a year-on-year increase of 37.38%[5] - Net profit attributable to shareholders was ¥183,697,243.65, reflecting a growth of 15.28% compared to the same period last year[5] - Total operating revenue for Q1 2022 reached ¥930.73 million, a 37.4% increase from ¥677.47 million in Q1 2021[48] - Net profit for Q1 2022 was ¥193.60 million, representing a 19.4% increase compared to ¥162.12 million in Q1 2021[48] - Earnings per share for Q1 2022 were ¥0.29, compared to ¥0.25 in Q1 2021[50] - Cash received from sales of goods and services in Q1 2022 was ¥732.57 million, an increase from ¥549.86 million in Q1 2021[50] Cash Flow - The net cash flow from operating activities was -¥19,559,417.10, a decrease of 130.85% year-on-year[5] - The net cash flow from operating activities decreased to -$19.56 million from $63.40 million year-over-year, indicating a significant decline in operational performance[54] - Cash received from operating activities totaled $751.78 million, an increase from $566.33 million, suggesting improved revenue generation[54] - Cash inflow from investment activities totaled $864.38 million, down from $1,076.48 million, reflecting a decrease in investment recovery[54] - Cash outflow for investment activities was $679.97 million, compared to $1,130.51 million in the previous period, showing a reduction in capital expenditures[54] - The net cash flow from financing activities was -$299,643.48, indicating that the company had a net outflow in this category[56] - The ending cash and cash equivalents balance was $353.16 million, down from $867.00 million, highlighting a significant decrease in liquidity[56] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to ¥6,093,177,254.01, an increase of 1.59% from the end of the previous year[7] - The total assets of the company reached approximately ¥6,093,177,254.01 as of March 31, 2022, compared to ¥5,997,600,248.38 at the end of December 2021, reflecting an increase of about 1.6%[42] - The total current assets increased to ¥4,154,053,584.91 from ¥4,064,479,153.32, representing a rise of about 2.2% year-over-year[39] - The total liabilities included accounts payable of ¥258,589,397.24, which increased from ¥163,094,814.55, marking a significant rise of about 58.6%[42] - The total liabilities decreased to ¥1,317.09 million in Q1 2022 from ¥1,415.11 million in Q1 2021[44] - The total equity increased to ¥4,776.08 million in Q1 2022 from ¥4,582.49 million in Q1 2021[44] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 47,555[16] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, accounting for 43.03% of total shares[16] - The second largest shareholder, Central Huijin Asset Management Co., Ltd., holds 15,551,120 shares, representing 2.47% of total shares[16] - The company repurchased 566,042 shares, reducing the total outstanding shares to 629,433,958[7] - The company has no pledged, marked, or frozen shares among the top ten shareholders[16] - The company has no related party or concerted action relationships with the top ten shareholders[19] Investment and Financial Products - The company has a total of 675,000 RMB in overdue principal from entrusted loans, with legal proceedings initiated to recover the amount[21] - The company has completed the granting of 510,000 restricted stocks under the 2021 stock incentive plan to 17 incentive objects[22] - The company has entrusted a total of 50 million RMB in non-principal guaranteed floating income financial products with an annualized return rate of 4.32%[25] - The company has also entrusted another 100 million RMB in non-principal guaranteed floating income financial products with an annualized return rate of 4.45%[25] - The company has a total of 100 million RMB in entrusted financial products maturing on June 6, 2022, with a return rate of 3.95%[25] - The company reported a total of ¥2,256,017,632.60 in fixed income products, with a weighted average interest rate of 3.55%[36] - The company has plans for market expansion and new product development, focusing on fixed income products to enhance revenue streams[36] Expenses - Total operating costs for Q1 2022 were ¥721.70 million, up 42.8% from ¥505.25 million in Q1 2021[48] - Research and development expenses for Q1 2022 totaled ¥27.97 million, a 44.7% increase from ¥19.36 million in Q1 2021[48] - Sales expenses in Q1 2022 were ¥353.21 million, up 60.5% from ¥219.75 million in Q1 2021[48] - Cash paid for employee compensation increased to $191.33 million from $146.47 million, reflecting higher personnel costs[54] - Cash paid for taxes rose to $74.98 million from $67.63 million, indicating an increase in tax obligations[54] Investment Income - The company reported a significant increase in investment income, reaching ¥1.19 million in Q1 2022 compared to a loss of ¥0.09 million in Q1 2021[48] - Cash received from investment income was $9.34 million, down from $13.43 million, showing a decline in investment returns[54] - Cash inflow from the recovery of investments was $855.02 million, down from $1,063.00 million, indicating a decrease in cash recovery from investments[54]